摘要
Background: Chronic idiopathic urticaria (CIU) is defined by the almost daily presence of urticaria for at least 6 weeks without an identifiable cause. Symptoms include short-lived wheals, itching, and erythema. CIU impedes significantly a patient’s quality of life (QoL). Levocetirizine is an antihistamine from the latest generation approved for CIU. Aim: To investigate the efficacy of levocetirizine, 5 mg, and placebo for the symptoms and signs of CIU, as well as for the QoL and productivity. Methods: The primary criteria of evaluation were the pruritus severity scores over 1 week of treatment and over 4 weeks. The QoL was assessed via the Dermatology Life Quality Index (DLQI). Results: Baseline pruritus severity scores were comparable in the two treatment groups (2.06 ±0.58). After 1week, levocetirizine was superior to placebo and demonstrated a considerable efficacy (difference = 0.78, P < 0.001). This efficacy was maintained over the entire study period (4 weeks, P < 0.001). The number and size of wheals were considerably reduced compared with placebo over 1 week and over the total treatment period (P ≤0.001). This was paralleled by an improvement in the QoL (DLQI: 7.3 units in the levocetirizine group and 2.4 units in the placebo group) and a higher productivity at work in the levocetirizine group (3.0 workdays lost per patient per month in the placebo group, 0.3 in the levocetirizine group). No unexpected adverse events occurred. Conclusions: Levocetirizine, 5 mg once daily, is an effective treatment for CIU, characterized not only by a rapid and sustained response, but also by an important improvement in QoL.
Background： Chronic idiopathic urticaria （CIU） is defined by the almost daily presence of urticaria for at least 6 weeks without an identifiable cause. Symptoms include short-lived wheals, itching, and erythema. CIU impedes significantly a patient＇s quality of life （QoL）. Levocetirizine is an antihistamine from the latest generation approved for CIU. Aim： To investigate the efficacy of levocetirizine, 5 rag, and placebo for the symptoms and signs of CIU, as well as for the QoL and productivity. Methods： The primary criteria of evaluation were the pruritus severity scores over 1 week of treatment and over 4 weeks. The QoL was assessed via the Dermatology Life Quality Index （DLQI）. Baseline pruritus severity scores were comparab Results： le in the two treatment groups （2. 06 ±0.58）. After lweek, levocetirizine was superior to placebo and demonstrated a considerable efficacy （difference = 0.78, P 〈0.001）. This efficacy was maintained over the entire study period （4 weeks, P 〈 0. 001）. The number and size of wheals were considerably reduced compared with placebo over 1 week and over the total treatment period （P ≤ 0. 001 ）. This was paralleled by an improvement in the QoL （DLQI： 7.3 units in the levocetirizine group and 2. 4 units in the placebo group） and a higher productivity at work in the levocetirizine group （3.0 workdays lost per patient per month in the placebo group, 0.3 in the levocetirizine group） . No unexpected adverse events occurred. Conclusions： Levocetirizine, 5 mg once daily, is an effective treatment for CIU, characterized not only by a rapid and sustained response, but also by an important improvement in QoL.
